About
Next generation of glyco-immune therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
321
By Phase
PHASE2: 2
By Status
TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06181227Lead Sponsor
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
PHASE2Terminated
21 participants
Started: Nov 30, 2023 · Completed: Apr 5, 2024
NCT05839041Lead Sponsor
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
PHASE2Active, not recruiting
300 participants
Started: May 2, 2023 · Completed: Sep 30, 2026
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...